Skip to content

Major Depression and AV101

Join a Research Study: Enrolling nationally from around the country

To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010].

The primary purpose of this research study is to evaluate the safety and effectiveness of the oral drug AV-101 (an antagonist of the glycine receptor) versus placebo. The study aims to determine if this experimental drug has antidepressant effects and fewer side effects than other novel treatments for depression.

We are enrolling moderately depressed individuals between the ages of 18 and 65 with hard-to-treat major depressive disorder. This inpatient study lasts up to 14 weeks and procedures include a medication taper, taking the research drug, taking placebo and 4 brain imaging scans. Optional procedures include a lumbar puncture and a catheter placement in the spine two times. After completing the study, participants receive short-term follow-up care at the NIH while transitioning back to a provider.

The study is conducted at the NIH Clinical Center in Bethesda, Maryland and enrolls eligible participants from across the USA. Travel arrangements are provided and costs are covered by NIMH (arrangements vary by distance). There is no cost to participate and compensation is provided.

First steps to participate include calling NIMH, learning specifics about the study, asking about your eligibility, and consenting to participate.